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Aims The early diagnosis of acute aortic dissection (AD) remains challenging. We sought to determine the utility of the
troponin-like protein of smooth muscle, calponin, as a diagnostic biomarker of acute AD.
Methods
and results
Immunoassays against calponin (acidic, basic, and neutral isoforms) were developed and the levels were compared in
a convenience sample of 59 patients with radiographically proven AD [34 males, age 59+ 15 (SD) years] vs. 158
patients suspected of having AD at presentation (116 males, age 63+15 years) but whose final diagnosis was not
AD. Basic calponin, which is the most specific and abundant in smooth muscle, and acidic calponin, respectively,
showed greater than two-fold and three-fold elevations in patients with acute AD. Diagnostic performance as deter-
mined by receiver-operating characteristics curve analysis showed that both acidic and basic calponin have the poten-
tial to detect AD in the first 24 h [respective areas under the curve (AUCs) 0.63 and 0.58], with superior
performance of basic calponin (when compared with acidic) in the initial 6 h (respective AUCs 0.63 and 0.67).
Conclusion Circulating calponin levels were elevated in acute AD compared with controls. These biomarkers have the potential
for use as an early diagnostic biomarker for acute AD.
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Introduction
Acute aortic dissection (AD) is potentially catastrophic.1,2 With
high mortality and morbidity, early diagnosis is a prerequisite for
improved treatment and survival.3 Recent advancements in the
understanding of the disease have not alleviated the challenges
faced by clinicians looking for an early diagnosis.4
Biochemical diagnosis has a great potential to aid in the early
diagnosis, and we have therefore developed biochemical markers
with this aim. The detection of release of smooth muscle proteins,
myosin heavy chain, and creatine kinase BB-isozyme from the
damaged aorta was shown to be useful within the initial
6–12 h.5–10 Another marker that can extend the time-window
to later stages would thus be helpful.
Given the widely accepted role of cardiac troponin as being the
single most reliable biomarker of myocardial ischaemia/infarc-
tion,11,12 we next pursued the diagnostic possibility of an assay
of a troponin counterpart of smooth muscle, calponin, in the
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present study.13 Calponin has three isoforms—acidic, basic and
neutral; basic calponin (also called h1) is the most abundant and
specific isoform in smooth muscle, whereas acidic and neutral cal-
ponin (also called h2) are not thought to be specific to smooth
muscle (i.e. found in both smooth muscle and non-smooth
muscle tissue) and are less abundant than basic calponin in
smooth muscle tissue.14 We describe our preliminary experience
with calponin as a diagnostic biomarker of acute AD.
Methods
Development of calponin assays
Monoclonal antibodies against full-length recombinant acidic calponin,
peptide fragments of basic calponin (peptides included amino acids
274–281 and 289–297 of basic calponin), and full-length recombinant
neutral calponin were derived, and sandwich-type enzyme immunoas-
says were generated according to the standard procedures and
protocols.
The dynamic range for acidic calponin was 0.03–50 ng/mL, basic cal-
ponin was 4.5–2500 ng/mL, and for neutral calponin was 5–700 ng/mL.
Cross-reactivity was defined when 50 ng/mL of sample was tested with
50 ng/mL of other sample added for acidic calponin was 8% against
basic calponin and 0% against neutral calponin, and for basic calponin
was 0% against acidic calponin and 0% against neutral calponin. Pre-
cision of the acidic calponin assay showed a coefficient of variance of
11% at 2.2 ng/mL and 11% at 140 ng/mL for the basic calponin assay.
Note that cross-reactivity and precision were not determined for
the neutral calponin because this assay was not further pursued after
initial analysis demonstrated a lack of correlation with AD.
The normal reference ranges are shown in Table 1. The normal
range as defined by the 95th percentile was 2.04 ng/mL for acidic cal-
ponin, 124.31 ng/mL for basic calponin, and 14.08 ng/mL for neutral
calponin.
Initial clinical studies in patients
with acute aortic dissection
Fourteen centres in the USA, Europe, and Japan participated in the
present study (see Appendix for a complete list of the participating
centres). Most were university-based tertiary centres or affiliated
centres where institutional review board approval was obtained. Con-
senting patients with suspicion of acute AD were enrolled. The suspi-
cion of AD had to be high enough to order an imaging test for
diagnosis. Confirmation of diagnosis was made by an imaging study.
Clinical data forms were completed for each of the patients with par-
ameters as developed by the International Registry of Acute Aortic
Dissection.2 Blood plasma was drawn on admission and used for
measurements in the present study.
Results
Patient demographics
Two hundred and seventeen patients were enrolled in the study
including 59 cases of radiographically proven acute AD and 158
‘controls’ with an initial suspicion of AD but a different final diag-
nosis as shown in Table 2. Of the 59 AD cases (59+14.5 years of
age), 34 were males (58%). The non-AD cases (63+14.8 years of
age) included 116 males (73%). Final diagnoses for the control
cohort included myocardial infarction (n ¼ 37), angina pectoris
(n ¼ 34), pulmonary embolism (n ¼ 3), non-dissecting thoracic
aortic aneurysm (n ¼ 17) or uncertain but not AD (n ¼ 67).
Thus, the non-AD controls who had been initially enrolled with
suspicion of acute AD had coronary heart disease in 45%, non-
dissecting aortic aneurysm in 11%, and pulmonary embolism in 2%.
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Table 1 Normal reference ranges for the assays
n Average Median SD 95th percentile 99th percentile
Acidic calponin (ng/mL) 218 1.19 1.01 0.92 2.04 5.73
Basic calponin (ng/mL) 282 44.09 31.74 41.81 124.31 162.15
Neutral calponin (ng/mL) 230 12.61 5.00 64.72 14.08 52.65
Table 2 Patient demographics of the study population




Type A 43 cases
Type B 15 cases
Type undetermined in one
case
Presentation time from onset
,6 h 16 cases (type A 14 cases, type B 2
cases)
6–12 h 20 cases (type A 16 cases, type B 4
cases)
12–24 h 22 cases (type A 13 cases, type B 9
cases)
Non-aortic dissection 158 cases (116 males, 63+14.8
years)
Final diagnosis
Myocardial infarction 37 cases
Angina pectoris 34 cases
Pulmonary embolism 3 cases
Thoracic aortic aneurysm 17 cases
Uncertain but not aortic
dissection
67 cases
Presentation time from onset
,6 h 52 cases
6–12 h 34 cases
12–24 h 72 cases
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Circulating calponin levels in patients
with acute aortic dissection
Calponin levels in the enrolled patients according to time from
onset (0–6, 6–12, 12–24 h) and type of dissection (all, type A,
type B) are shown in Figure 1. Comparison of the dynamic range
of elevations in the levels in patients as defined by the 75th percen-
tile vs. the 95th percentile of the normal range indicated that acidic
calponin showed a greater than two-fold increase for all dissec-
tions presenting within the first 6 h of symptom onset (4.10 ng/
mL, n ¼ 16; normal reference, 2.04 ng/mL) which was particularly
notable for type A (4.70 ng/mL, n ¼ 14) when compared with
type B patients (2.84 ng/mL, n ¼ 2). Type A patients in the
6–12 h range also showed elevations (5.08 ng/mL, n ¼ 16) but
not type B patients (2.43 ng/mL, n ¼ 4). Levels began to drop-off
in the 12–24 h range for type A patients (3.23 ng/mL, n ¼ 13)
and were not significantly elevated in type B patients (2.64 ng/
mL, n ¼ 9). Patients without AD did not show elevations at any
of the examined time points (0–6 h, 2.29 ng/mL, n ¼ 52; 6–12 h,
2.65 ng/mL, n ¼ 34; 12–24 h, 2.62 ng/mL, n ¼ 72).
Basic calponin showed a more than three-fold increase at
377.56 ng/mL (normal reference, 123.31 ng/mL) for all dissections
when sampled within the first 6 h of symptom onset (n ¼ 16)
which was similar for type A (379.04 ng/mL, n ¼ 14) and type B
patients (316.24 ng/mL, n ¼ 2). The 6–12 h time-window
showed similar, greater than three-fold, elevations in type A
patients (348.79 ng/mL, n ¼ 16) but with a drop-off for type B
patients (171.96 ng/mL). Levels in both type A and type B patients
had fallen in the later 12–24 h group (all patients, 169.24 ng/ml,
n ¼ 22; type A patients, 172.05 ng/ml, n ¼ 13; type B patients,
171.96 ng/ml, n ¼ 9). Patients without AD did not show elevations
at any of the examined time points (0–6 h, 166.70 ng/mL, n ¼ 52;
6–12 h, 179.41 ng/mL, n ¼ 34; 12–24 h, 159.98 ng/mL, n ¼ 72).
Neutral calponin did not show elevations in any AD patient
regardless of type or time from onset of symptoms (0–6 h,
5.11 ng/mL, n ¼ 16; 6–12 h, 18.17 ng/mL, n ¼ 21; 12–24 h,
13.19 ng/mL, n ¼ 22; normal reference, 14.08 ng/mL). As
expected, neutral calponin did not show elevations in non-AD
controls (0–6 h, 15.03 ng/mL, n ¼ 52; 6–12 h, 8.19 ng/mL,
n ¼ 34; 12–24 h, 12.30 ng/mL, n ¼ 72).
Thus, acidic and basic calponins showed greater than two-fold
and three-fold elevations, respectively, during the initial 6 h with
type A and remained elevated through to 12 h. For type B dissec-
tion, acidic and basic calponin levels were elevated in the very early
presenters (0–6 h) but not afterward. Neutral calponin did not
show disease-associated changes and was not further pursued.
Further analysis according to final diagnosis was done for acidic and
basic calponin. As shown in Figure 2, AD clearly showed elevations
with a marked increase in the type A patient for basic calponin.
Figure 1 Box plots of acidic and basic calponin in patients with aortic dissection according to type (all, type A, type B) and time after
symptom onset (0–6, 6–12, 12–24 h).
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Diagnostic performance of calponin
assays
Sensitivity and specificity of detection of acute AD were also
analysed by receiver-operating characteristics (ROC) curves. The
area under the curve (AUC) values as a collective parameter
reflective of diagnostic accuracy is shown in Table 3. Overall, for
all of the patients examined within the initial 24 h period, acidic cal-
ponin showed highest AUC values at 0.63 followed by basic calpo-
nin at 0.58. Higher values were seen for type A patients alone at
0.65 and 0.59, respectively. For the early samples alone (0–6 h),
basic calponin showed highest AUC values (0.67) followed by
acidic calponin (0.63). Type A showed similar AUC values of
0.65 for either acidic or basic calponin. Type B showed an AUC
of 0.82 for basic calponin but the sample size (n ¼ 2) limits the
confidence of this observation.
The optimal clinical decision limit value was determined from
these ROC curve analyses which showed that the optimal value
for acidic calponin was 2.8 ng/mL which resulted in a sensitivity
of 50% and specificity of 87% for the initial 6 h and 2.3 ng/mL
which resulted in a sensitivity of 58% and specificity of 72% for
the initial 24 h period. Similarly, the optimal value for basic calpo-
nin was 159 ng/mL which resulted in a sensitivity of 63% and speci-
ficity of 73% for the initial 6 h and 139 ng/mL which resulted in a
sensitivity of 50% and specificity of 66% for the initial 24 h
period. According to type, type A showed an optimal value for
acidic calponin at 2.8 ng/mL which resulted in a sensitivity of 50%
and specificity of 87% for the initial 6 h and 2.3 ng/mL which
resulted in a sensitivity of 58% and specificity of 72% for the
initial 24 h period. Similarly, the optimal value for basic calponin
was 159 ng/mL which resulted in a sensitivity of 64% and specificity
of 73% for the initial 6 h and 141 ng/mL which resulted in a sensi-
tivity of 50% and specificity of 67% for the initial 24 h period.
The predictive values (negative and positive) as calculated with a
prevalence of 1 in 10 000 were 0.84 and 0.56 in the initial 6 h and
0.84 and 0.41 in the initial 24 h, respectively, for acidic calponin and
0.86 and 0.44 in the initial 6 h and 0.80 and 0.33 in the initial 24 h,
respectively, for basic calponin (Table 3). Importantly, both acidic
and basic calponin had higher negative predictive values.
Discussion
Biochemical diagnosis of acute aortic
dissection by circulating calponin levels
We have developed immunoassays against a troponin counterpart
of smooth muscle, calponin, and have examined the circulating
levels in acute AD and a number of non-dissection patients. As
expected, the immunoassay developed against basic calponin,
which is the most specific and abundant isoform in smooth
muscle, showed the greatest elevations. Acidic calponin also
showed diagnostic elevations, but disease-associated changes in
neutral calponin levels were non-diagnostic. Analysis by type and
time after onset showed that acidic calponin detects acute AD
within the first 12 h with superior performance in type A patients.
Basic calponin showed superior performance for the first 6 h.
Importantly, calponin measurements allowed for detection of the
disease in patients with a more delayed presentation (out to
12 h) which should be a welcome addition for diagnostic use in
comparison with smooth muscle myosin heavy chain which pre-
viously has been shown to possess superior accuracy for patients
presenting within 6 h after onset.
One of the strengths of the present study was that diagnostic
performance of the assays was determined in patients who were
enrolled on the basis of a clinical suspicion of acute AD and not
by comparison with healthy controls. Thus, the test’s accuracy
reflects the ‘real-world’ conditions. We do note that many of
the participating centres were major aortic centres (e.g. tertiary
centres) and thus the diagnostic approach may not accurately
Figure 2 Acidic and basic calponin levels in patients examined in the present study according to final diagnosis. MI, myocardial infarction;
PE, pulmonary embolism; TNDA, thoracic non-dissecting aneurysm; ADþ(B), type B aortic dissection; ADþ(A), type A aortic dissection;
AD(2), aortic dissection type not determined; AD(2), uncertain final diagnosis but not aortic dissection.
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Table 3 Diagnostic performance of the assays




















Early samples: AD (0–6 h) vs. non-AD (0–6 h)
Acidic calponina 16 52 0.63 0.11 14 52 0.66 0.07 2 52 0.46 0.85
Basic calponinb 16 52 0.67 0.04 14 52 0.65 0.10 2 52 0.82 0.13
Neutral calponin 16 52 0.42 0.33 14 52 0.39 0.20 2 52 0.64 0.49
All samples AD: (0–24 h) vs. non-AD (0–24 h)
Acidic calponinc 59 158 0.63 0.00 43 158 0.65 0.00 15 158 0.54 0.57
Basic calponind 59 158 0.58 0.08 43 158 0.59 0.08 15 158 0.54 0.63
Neutral calponin 59 158 0.50 0.99 43 158 0.49 0.77 15 158 0.56 0.48
NPV, negative predictive value; PPV, positive predictive value.
aNPV: 0.84; PPV: 0.56.
bNPV: 0.86; PPV: 0.44.
cNPV: 0.84; PPV: 0.41.














reflect the use in the community setting. Further, although we have
examined a large number of patients of this rather uncommon
disease, the analysis according to type and time after onset resulted
in smaller subgroups which limited the number of patients in each
subset. This limits our ability to study the diagnostic accuracy in
certain cohorts (e.g. high AUC values in type B dissection for
basic calponin based on two diseased cases).
Additionally, as with all other blood tests, interpretation within
the context of the clinical presentation and examination is needed.
As entry into the present study required a high enough index of
suspicion for the clinician to order some type of imaging study,
the clinical suspicion for acute AD was reasonably high in
control patients as well as the cases. We did not study conditions
which primarily affect the gastrointestinal tract where one might
suspect to also see elevations in calponin due to damaged
smooth muscle. Also, since the acidic isoform of calponin is
present in neurological tissue, acute neurological conditions
might show elevations in this marker thus limiting the diagnostic
accuracy in patients with neurological signs.
An important corollary to the possibility of having biomarkers
for AD is the consideration of how such tools might interplay
with diagnostic imaging. Currently, the only way to reliably diag-
nose acute AD is with imaging, typically either CT scanning or
transesophageal echocardiography.15,16 Since there is still great
uncertainty how to optimize the diagnostic approach in patients
suspected of having acute AD, biochemical diagnosis may
improve upon this as a screening tool with emphasis on rule-out.
In conclusion, we report an initial study on the development of
assays against circulating smooth muscle troponin-like protein, cal-
ponin, and its use in diagnosis of acute AD. The results of this pre-
liminary experience using an initial assay show moderate
sensitivities and specificities with negative predictive values which
should be further improved upon. These findings suggest that
improvement in the diagnostic performance of the assay through
further technical improvements is necessary for it to be ready
for production and commercial use.
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Ford Hospital, Detroit, MI, USA); Robert Birkhahn (New York
Methodist Hospital, Brooklyn, NY, USA); Francis Counselman
(Eastern Virginia Medical School, Norfolk, VA, USA); Frank
Peacock (Cleveland Clinic, Cleveland, OH, USA); Craig Basson
(Cornell University, New York, NY, USA); Arturo Evangelista
(Hospital General Vall Hebron, Barcelona, Spain); Carlo Rosen,
Natan Shapiro (Beth Israel Deaconess Medical Center, Boston,
MA, USA); Robert Siegel (Cedars Sinai Medical Center, Los
Angeles, CA, USA); Adam Singer (Stony Brook University Hospital,
Stony Brook, NY, USA); Antonella Zizza, Federico Sabino, Isabella
Longo (ISBEM, Brindisi, Italy); Stefano Lagravinese, Rosaria Galdi,
Elena Gianicolo (University of Pisa and ISBEM, Italy); Eduardo
Bossone, Enzo Sbenaglia [National Research Council Institute of
Clinical Physiology (CNR IFC), Lecce, Italy]; Santi Trimarchi,
Viviana Grassi (IRCCS Policlinico San Donato, Milan, Italy);
Massimo Villani, Paolo Fellini, Silvano Fracella, Francesco Magliari,
Massimiliano Garzya (Vito Fazzi Hospital, Lecce, Italy); Jorge
Antonio Salerno Uriarte, Matteo Tozzi, Alberto Limido (Fonda-
zione Macchi Hospital, Varese, Italy); Luigi Tupputi De Luca, Vito
Paradiso, Andreas Paramithiotis (Policlinico Hospital, Bari, Italy);
Attilio Renzulli, Egidio Bevacqua, Barbara Impiombato (Mater
Domini Hospital, Catanzaro, Italy); Stefano Messina, Saverio
Rega, (Martiri di Villa Malta Hospital, Salerno, Italy); Filippo Crea,
Federica Tarantino (A. Gemelli Policlinico, Rome, Italy); Giuseppe
Di Benedetto, Antonello Panza (San Giovani di Dio Hospital,
Salerno, Italy); Giampiero Esposito, Rocco Antonio Pennetta
(Citta` di Lecce Clinic, Lecce, Italy); Paolo Righini (Humanitas Hos-
pital, Milan, Italy); Ettore De Lorenzi (Verri Delli Ponti Hospital,
Scorrano of Lecce, Italy); Giovanni De Rinaldis, Giordano
Calabrese, Pietro De Angelis (San Giuseppe Hospital, Copertino
of Lecce, Italy); Roberto Chiesa, Gloria Esposito (IRCCS
S. Raffaele, Milan, Italy); Gianfranco Ignone (A. Perrino Hospital,
Brindisi, Italy); Piergiovanni Crocco (San Giovani di Dio Hospital,
Salerno, Italy); Giuseppe Rosato, Giovanni Stanco (S.G. Moscati
Hospital, Avellino, Italy); Marcello Costantini (S. Caterina
Novella Hospital, Galatina of Lecce, Italy); Ernesto Lupo (SS.
Annunziata Hospital, Taranto, Italy); Jim Froehlich (University of
Michigan, Ann Arbor, MI, USA); Daigo Sawaki, Ryozo Nagai (The
University of Tokyo, Tokyo, Japan).
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